Otsuka´s Subsidiary Avanir Pharmaceuticals Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer´s Dementia (138KB)
(WorldNews Japan)

March 25, 2019 For Immediate Release Company name Otsuka Holdings Co., Ltd. Representative Tatsuo Higuchi President and Representative Director, CEO Code number 4578 First Section , Tokyo Stock Exchange Inquiries Yuji Kogure Director, Investors Relations Department Otsuka`s Subsidiary Avanir Pharmaceuticals Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer`s Dementia Otsuka Pharmceutical Co., Ltd. (Otsuka) announces that its U.S. -based, indirect subsidiary Avanir Pharmaceuticals, Inc. (Avanir) reports results from the first study of its phase 3 clinical development program investigating the efficacy, safety...